AstraZeneca is readying to file the first of a new portfolio of targeted cancer drugs for regulatory approval, moving to cement its position in one of the fastest-growing corners of the oncology market.
AstraZeneca is readying to file the first of a new portfolio of targeted cancer drugs for regulatory approval, moving to cement its position in one of the fastest-growing corners of the oncology market.